Misplaced Pages

Omidenepag

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Medication

Pharmaceutical compound
Omidenepag
Clinical data
Trade namesEybelis, Omlonti
Other namesUR-7276, DE-117, Omidenepag isopropyl (JAN JP)
Routes of
administration		Topical eye drops
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • Propan-2-yl 2-methyl]pyridin-2-yl]amino]acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC26H28N6O4S
Molar mass520.61 g·mol
3D model (JSmol)
SMILES
  • CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1
InChI
  • InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31)
  • Key:YHGSTSNEOJUIRN-UHFFFAOYSA-N

  • InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30)
  • Key:VIQCWEGEHRBLAC-UHFFFAOYSA-N

Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.

Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022.

Medical uses

Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.

Adverse effects

The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.

Pharmacology

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. Omidenepag is a selective prostaglandin E2 receptor agonist.

History

Omidenepag was developed by Ube Industries and Santen Pharmaceutical.

References

  1. ^ "Omlonti- omidenepag isopropyl solution/ drops". DailyMed. 30 September 2022. Retrieved 16 October 2022.
  2. ^ "Drug Approval Package: Omlonti". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.
  3. ^ Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.
  4. "Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension" (Press release). Santen. 26 September 2022. Retrieved 1 October 2022 – via Business Wire.
  5. "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. Archived from the original on 8 January 2022. Retrieved 8 January 2022.
  6. Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.
  7. Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.

External links

Drugs used for glaucoma preparations and miosis (S01E)
Sympathomimetics
Parasympathomimetics
muscarinic
muscarinic/nicotinic
acetylcholinesterase inhibitors
Carbonic anhydrase inhibitors/
(sulfonamides)
Beta blocking agents
Prostaglandin analogues (F2α)
Other agents
Portal: Categories: